<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663559</url>
  </required_header>
  <id_info>
    <org_study_id>SOGUG/0107</org_study_id>
    <nct_id>NCT00663559</nct_id>
  </id_info>
  <brief_title>Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy</brief_title>
  <acronym>SOGUG/0107</acronym>
  <official_title>Study Phase II to Determinate the Efficacy of Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Oncology Genito-Urinary Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Oncology Genito-Urinary Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determinate the efficacy of Sunitinib in patients with renal&#xD;
      cells carcinoma metastasic or locally avanced in patints not candidates to inicial curative&#xD;
      nefrectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study phase II in with one arm in patients with renal cells carcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>every 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global survival</measure>
    <time_frame>At last contact date or death date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response global</measure>
    <time_frame>Every 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Every 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Security and tolerability of Sunitinib</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Carcinoma Renal Cells</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This study has only one arm with Sunitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>Sunitinib 50mg oral in the morning during 4 weeks with 2 weeks of break.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must give their written informed consent before any procedure related to the&#xD;
             study is performed.&#xD;
&#xD;
          -  Patients with renal clear cell carcinoma metastatic or locally advanced,&#xD;
             histologically or cytologically documented.The patients with metastasic disease must&#xD;
             be not condidated to curative nefrectomy as investigator criteria.&#xD;
&#xD;
          -  Assessable or measurable disease according to RECIST criteria. The lesions previosly&#xD;
             radiated is not considered as target.&#xD;
&#xD;
          -  Ages equal or superior to 18 years old.&#xD;
&#xD;
          -  ECOG ≤ 1&#xD;
&#xD;
          -  Patients with a life expectancy superior to 12 weeks.&#xD;
&#xD;
          -  Patients with adequate organic function, according to the following criteria:&#xD;
&#xD;
               1. . Medular reserve: Neutrophils absolute count≥ 1.5 x 10^9/L Platelets ≥ 100 x&#xD;
                  10^9/L Haemoglobin ≥ 9g/dl&#xD;
&#xD;
               2. . Hepatic function: Total bilirubin &lt; 1.5 times the superior limit of normality&#xD;
                  ALT and AST &lt; 2.5 times the superior limit of normality (&lt; 5 times the superior&#xD;
                  limit of normality in case of liver failure due to cancer)&#xD;
&#xD;
               3. . Seric Albumin ≥ 1.5 times the superior limit of normality&#xD;
&#xD;
               4. . Renal Function: Cleary creatinine &gt; 30ml/min&#xD;
&#xD;
               5. . FEVI &gt; LIN according to ECO or MUGA&#xD;
&#xD;
          -  Patients who are capable of accomplishing the study's requirements and without any&#xD;
             impediments to follow the instructions while on study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women. Women of fertile age must have a negative result in&#xD;
             the pregnancy test performed 7 days before the beginning of the administration of the&#xD;
             study medication. Both men and women included in the study must use an adequate&#xD;
             contraceptive method.&#xD;
&#xD;
          -  Patients that have received sistemic treatment previous to metastasic disease.&#xD;
&#xD;
          -  Previous nefrectomy.&#xD;
&#xD;
          -  Mayor Surgery, radiotherapy or sistemic therapy received in the last 3 weeks previous&#xD;
             to the inclusion of the patient in the study, except paliative radiotherapy upper no&#xD;
             target lesions.&#xD;
&#xD;
          -  Radiotherapy upper &gt; 25% bone marrow.&#xD;
&#xD;
          -  Patients that are participating in any clinical trial.&#xD;
&#xD;
          -  Patients with a primary cancer diagnosis in thast 3 years, except superficial&#xD;
             basaliomas, superficial escamous carcinoma or in situ cervix carcinoma with aducuate&#xD;
             treatment.&#xD;
&#xD;
          -  Following events in the last 12 months previous to begin the treatment: myocardial&#xD;
             infarction, unstable o severe angina, coronary/periferic place of arterial by-pass,&#xD;
             congestive cardiac insufficiency, brain-vascular accident included transitory ischemia&#xD;
             or lung embolism.&#xD;
&#xD;
          -  Arterial uncontrolled hypertension nor controlated with drugs ( &gt;150/100 mmHg despite&#xD;
             adequate medical treatment).&#xD;
&#xD;
          -  Cardiac arrhythmia with grade NCI CTCAE ≥2, auricular fibrillation all grade and/or&#xD;
             QTc interval&gt; 450mseg in men and &gt; 470 mseg in women.&#xD;
&#xD;
          -  Actually treatment with therapeutic dose with acenocumarol (except low dose for deep&#xD;
             venous thrombosis).&#xD;
&#xD;
          -  Patients that present previously known positive serology for HIV.&#xD;
&#xD;
          -  Abuse of substances, clinical conditions, psychological or social, that may interfere&#xD;
             with the patient's participation in the study or with the evaluation of the study's&#xD;
             results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Luís González Larriba, MD</last_name>
    <role>Study Chair</role>
    <affiliation>SOGUG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital CLINIC</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal</keyword>
  <keyword>Sunitinib</keyword>
  <keyword>Unresectable and/or metastatic renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

